Options: Hide MedDRA Preferred Terms
Information about indications was extracted from the indications and usage sections of the labels.
Indication | Labels | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast cancer | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
Breast cancer stage IV | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
Cardiotoxicity | x | |||||||||||||||||||||
Colorectal cancer | x | x | x | x | x | x | x | x | x | x | x | |||||||||||
Colorectal cancer metastatic | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||
Colorectal carcinoma | x | x | x | x | x | x | x | x | ||||||||||||||
Hyperbilirubinaemia | x | |||||||||||||||||||||
Neoplasm | x | x | x | x | ||||||||||||||||||
Neoplasm malignant | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||||||
Renal impairment | x | x | x | x | x | x |
standard – alternative
100% | ||
75% | ||
50% | ||
10% | ||
frequent (1% to 100%) | ||
infrequent (0.1% to 1%) | ||
rare (<0.1%) | ||
postmarketing | ||
0% | ||
no frequency information | ||
not found on label |